RE:RE:RE:RE:RE:RE:stock price?Ya i see what youre saying and it makes sense. I guess what i meant by break out is the possibility of a clinical phase 2 or even phase 3 trial of a NASH drug getting picked up by big pharma. Some instances big pharma have paid over 1 BLN for a drug. So lets say the potential is there for a breakthrough from NASH. If their drug is purchased by a giant it would blow up the share price. I agree breathtec should definitly not be their focus. Again everything i'm saying is a big IF but i think we are likely to see 1$ out of this in the near future when NASH disease is more widely known, causing hype. Also like you say if theres a partnership then ya bud hold on to your you know what. I've been in breathtec since 2016 i believe. 0.09 cents anyway. Holding long term.
AMG63USA wrote: A year from breaking out? Ok...but what does that mean? A year from getting away from a 10M USD market cap? Algernon Pharmaceuticals (Algernon) has increased it's shots on goal thus far by at least 4 fold since our one trick pony breathalyzer - NASH,CKD,IBD, with CD & UC (Crohns & Colitis) on deck. It's simply unreasonable to have breathalyzer technology valued as much as 30 times more by our sister company which is no closer to commercialization than Algernon. Nor is there any definitive comparison to how big either market cap is ultimately. The word "global" is thrown around regarding both agreements with the University of Florida for the "FAIMS" patent.
So all things being equal...it's simply the Hype Of The Story (USD300M) that has always separated the two in terms of valuation. A Love/Hate relationship. Breathtec's story was never really told and suffered a slow and painful exit. Enter Algernon Pharmaceuticals. A New Story with a lot to be hyped about. News release after news release since the "acquisition" of Breathec/Nash Pharma. Sixteen (16) news releases since October 2018. Zero (0) definitive reaction. Enter Renmark Financial Communications to drive the narrative towards potential investors familiar with All Things Pharmaceuticals.
Therefore, my belief is a "break out" if you will, will rely on getting our message out to new investors. However, our number 1 concern is Big Pharma. That's our real target audience - not bargain bin shoppers. Beyond the start of clinical trials, a release of positive news regarding partnership(s) could trigger your definition of a breakout. A market cap below 50M is defined as a Nano Cap stock. My definition of a break out starts beyond a 50M USD market cap. Hovering around 10M market cap is like a Nano Nano Cap (below grade) for A Clinical Stage Drug Development Company.
Bottom line, $1USD (50 Cent Pre/Split) is my first floor launching pad.
Just 1 opinion,
/////AMG